AaTs-1, a Tetrapeptide from Scorpion Venom Mitigates Demyelination and Neuroinflammation in a Cuprizone-Induced Model of Multiple Sclerosis
AaTs-1, a Tetrapeptide from Scorpion Venom Mitigates Demyelination and Neuroinflammation in a Cuprizone-Induced Model of Multiple Sclerosis
Abstract
Purpose
This study focuses on the evaluation of the therapeutic potential of Tetrascorpin-1 (AaTs-1), a tetrapeptide isolated from Androctonus australis hector venom, proposed as a putative formyl peptide receptor 2 (FPR2) antagonist, in a cuprizone-induced murine model of Multiple sclerosis (MS), a chronic autoimmune and inflammatory disease of the central nervous system.
Methods
Acute demyelination was induced in mice by administering cuprizone (0.2% w/w in the diet) for six weeks. During the sixth week of cuprizone intake, demyelinated mice received intranasal administration of AaTs-1 at a dose of 50–100 µg/kg for five consecutive days, with 24-hour intervals between treatments.
Results
Behavioral assessments, immunological assays, and histological analyses revealed that AaTs-1 improved body weight, reduced behavioral impairments and mitigated neuroinflammation by suppressing astrogliosis and microgliosis, lowering myeloperoxidase (MPO) and nuclear factor kappa B (NF-κB) levels, and downregulating proinflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), while upregulating the anti-inflammatory cytokine interleukin-10 (IL-10) in serum. Moreover, AaTs-1 restored oxidative balance by reducing nitric oxide (NO), hydrogen peroxide (H₂O₂), and malondialdehyde (MDA) levels and enhancing catalase activity and glutathione (GSH) levels.
Conclusion
Overall, our findings indicate that AaTs-1 confers significant neuroprotective effects by limiting neuroinflammation and oxidative stress, thereby enhancing remyelination and functional recovery.
Moussaoui, H., Amarni, M., Ladjel-Mendil, A. et al. AaTs-1, a Tetrapeptide from Scorpion Venom Mitigates Demyelination and Neuroinflammation in a Cuprizone-Induced Model of Multiple Sclerosis. Int J Pept Res Ther 32, 62 (2026). https://doi.org/10.1007/s10989-026-10842-2
